Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank

Circ Genom Precis Med. 2023 Apr;16(2):e003835. doi: 10.1161/CIRCGEN.121.003835. Epub 2023 Mar 3.

David E Lanfear^{1

2}, Jasmine A Luzum^{1

3}, Ruicong She⁴, Jia Li⁴, Hani N Sabbah², Nicole Zeld¹, Bin Liu⁴, Edward Peterson⁴, L Keoki Williams¹

¹ Center for Individualized and Genomic Medicine Research (CIGMA), Department of Internal Medicine, Henry Ford Hospital, Detroit, MI (D.E.L., J.A.L., N.Z., L.K.W.).
² Heart and Vascular Institute (D.E.L., H.N.S.), Henry Ford Health System, Detroit, MI.
³ Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI (J.A.L.).
⁴ Department of Public Health Sciences (R.S., J.L., B.L., E.P.), Henry Ford Health System, Detroit, MI.

No abstract available

Keywords: adrenergic beta antagonists; genome wide association study; heart failure; precision medicine; survival.

Publication types